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Published by Elsevier Inc.CORRESPONDENCELetters to the EditorEthnic Diversity and
Immunological Barriers
in Heart TransplantationWith great interest we read the recent article by Morris et al. (1)
reporting on panel reactive antibody (PRA)-associated ethnic dis-
parities of sensitization status and post-heart transplant outcomes
in a total of 19,704 patients listed for heart transplantation. African
American heart transplant (HT) recipients experienced more graft
failure than other ethnicities. Human leukocyte antigen (HLA)
mismatch was related to graft failure, and ethnic subpopulations
were more likely to have HLA mismatch than white HT recipients.
By using Cox proportional regression to adjust for potential con-
founders, African American race, Hispanic ethnicity, and sensiti-
zation were reported to be independent predictors of higher
incidences of graft failure (1).
We would greatly appreciate the authors’ comments on whether
an attempt was made to evaluate the inﬂuence of different induc-
tion therapies and immunosuppressive treatment regimens on
outcomes. Maintenance levels of immunosuppressant drugs within
therapeutic ranges are essential for successful preservation of graft
function. Several studies were undertaken to investigate the re-
lationships among genotype, pharmacokinetics, and therapy out-
come. Ethnic disparities can be explained in part by genetically
determined polymorphisms of xenobiotic-metabolizing enzymes,
transport proteins, and drug targets (2,3). To improve outcomes in
high-risk subpopulations, immunosuppressive therapies must be
individualized accordingly. Strategies aimed at improving trans-
plant outcomes might include the use of more aggressive induction
therapies, higher immunosuppressive doses, different combinations
of immunosuppressive agents, tighter post-transplant monitoring
and control of concurrent disease states (4).
In sensitized patients, a ﬁnal prospective lymphocyte crossmatch
(CXM) is considered the sine qua non condition for transplantation.
More than 10% and 25% of new listings on the pediatric and adult
heart transplantation waiting list, respectively, in 2004 required
prospective CXM according to the United Network of Organ
Sharing (UNOS) (5). Standard complement dependent cytotoxicity
(CDC) assays have been demonstrated to be rather insensitive
in detecting circulating HLA antibodies compared to novel
solid-phase or microsphere-based assays. It has been shown that
standard CDC-based PRA testing failed to identify anti-HLA-
antibodies in 25% of transplantation patients who possessed anti-
bodies as detected by ﬂow cytometry (6). Novel immunological
assays facilitate the highly sensitive and quantitative detection of
both class I and II alloantibodies. Virtual CXM based on high-
resolution HLA and non-HLA alloantibody detection techniques
providing full antibody speciﬁcity disclosure compared to conven-
tional PRA assays allows prediction of compatible donor–recipientcombinations (7). Other allogeneic non-HLA antigens that have
been associated with poor allograft survival, such as MICA, are not
expressed on peripheral blood lymphocytes, rendering the traditional
CXM to donor lymphocytes unsuitable for detecting this class of
clinically relevant alloantibodies (8). To this end, it is also possible to
detect antibodies reactive to MICA and HLA-C antigens,
completing the repertoire of potentially clinically relevant HLA an-
tibodies. Especially in high-risk ethnic subpopulations, a virtual
CXM might improve outcomes while minimizing the risk for
post-transplant antibody-mediated rejection episodes.
The investigators should be commended because their study
adds an important piece of evidence to the ﬁeld and underscores the
importance of individualized management of transplantation re-
cipients. Individualized strategies accounting for interindividual
genetic variability of donors and recipients will become increasingly




*Department of Cardiovascular Surgery
German Heart Center Munich






1. Morris AA, Cole RT, Veledar E, et al. Inﬂuence of race/ethnic differ-
ences in pre- transplant panel reactive antibody on outcomes in heart
transplant recipients. J Am Coll Cardiol 2013;62:2308–15.
2. Kurzawski M, Drozdzik M. Pharmacogenetics in solid organ trans-
plantation: genes involved in mechanism of action and pharmacokinetics
of immunosuppressive drugs. Pharmacogenomics 2013;14:1099–118.
3. McGraw J, Waller D. Cytochrome P450 variations in different ethnic
populations. Expert Opin Drug Metab Toxicol 2012;8:371–82.
4. Deierhoi MH, Haug M III. Review of select transplant subpopulations
at high risk of failure from standard immunosuppressive therapy. Clin
Transplant 2000;14:439–48.
5. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical
application of the virtual crossmatch. Pediatr Transplant 2007;11:650–4.
6. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA
antibody detection: technology emulating biology. Immunol Res 2004;
29:41–54.
7. Deutsch MA, Kauke T, Sadoni S, et al. Luminex-based virtual cross-
matching facilitates combined third-time cardiac and de novo renal
transplantation in a sensitized patient with sustained antibody-mediated
cardiac allograft rejection. Pediatr Transplant 2010;14:E96–100.
8. Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related
to adverse outcome in heart transplant recipients. J Heart Lung Trans-
plant 2009;28:305–11.
